Psycho-Babble Alternative | about alternative treatments | Framed
This thread | Show all | Post follow-up | Start new thread | List of forums | Search | FAQ

Re: oops.....forgot the links and » Larry Hoover

Posted by chemist on July 7, 2004, at 10:36:41

In reply to Re: oops.....forgot the links and » joebob, posted by Larry Hoover on July 3, 2004, at 11:02:48

> > then had a crash...
> > maybe dr bob should start a board for xp users with strange os problems that can lead to confusion and anxiety :)
> >
> > anyhow heres the stuff i would like your commments on if you have the time and interest
> >
> > http://www.biopsychiatry.com/aniracetam.htm
>
> Fascinating. It would appear that the -acetams, as a class, have a similar chemistry. The -acetam ring opens, and what is left is an N-substituted GABA. I hope chemist comes back into this discussion. That is his realm.
>
> > and
> >
> > http://lifeextensionvitamins.com/serphosser.html
>
> Interesting that they distinguish between the effects of phosphatidyl serine and phosphated serine. It is quite true that the fatty acids in the phosphatide are subject to oxidative degradation (rancidity).
>
> These are both good leaping-off points for further study. I shall have to come back to this all after some research and cogitation.
>
> Lar

hello there, chemist here...sorry for being out of touch...the pubs i have in my files (about 20 or so) are mostly roeated to synthesis and characterization of nootropics. let me ramble on a bit...first off, the common theme for almost every nootropic is the presence of a 2-oxopyrrolidine structure. almost every derivative that is found to be active that is not similar to the piracetam structure (e.g. AChE/BChE inhibitor analouges of huperzine A, see j. med. chem. 38:3645-3651, 1995) must be substituted in at least one nitrogen position. in this case, galanthamine, E-2020 and huperzine A are all selective for AChE over BChE and are reversible inhibitors of AChE that do not acetylate the active site. in the compounds where the 2-oxopyrrolidine ring is absent, it appears that substitution of a primary amine and/or pyridinone nitrogen must be done to produce a drug with sub-micromolar binding affinity. it gets messier. so far, we've been looking at AChE (reversible) inhibition. however, there's the NMDA bit (and yes, also KA and AMPA). competive/non-competitive NMDA antagonists are targeted in cell death via cerebral ischemia (see j. med. chem. 37:3008-3015, 1994, e.g.): here, a series of 2-amino-alpha-thienylbenzeneethanamines was studied, and the best neuroprotectant was a derivative that was methylated at - you guessed - a primary amine. in this pub, the results were generalized to a small alkyl substituent on the alpha-nitrogen as well as a substitution in the ortho position of the thiophene ring, so looking at ortho directors or para/meta deactivators. in keeping with the ischemia theme, there are a host of adenosine receptor (sub-receptor, really) agonists (j. med. chem 46:3775-3777, 2003; j. med. chem. 46:794-809, 2003; j. med. chem 36:2508-2518, 1993, e.g.). in the first of the 3 refs, they look at sub-nM affinities of (naturally) N-substituted 4'-thio analogues of Cl-IB-MECA, which had a K_{i} of about 1 nM for the A_{3} subreceptor. this is interesting in that by halogenating IB-MECA, K_{i} dropped and selectivity for A_{3} over A_{1} and A_{2A} increased. the now, IB-MECA's main skeleton is a purine, as you would expect for an adenosine analogue. the chloro substituent in between the 2 nitrogens in the pyrimidine, and the primary amine is meta to the Cl, so this makes sense as far as enhancing binding affinity (the amino group here - as in the case of the NMDA inhibitors - is methylated). no ring cleavage so far, from what i have, but again, if i were to look, i'd go for an activated ortho/para position, hence the chloro. the second 2 pubs deal with A_{1} selective antagonists, and are xanthine derivatives, so you have a purine-based skeleton including a doubly-bound oxygen, making these compounds (in the QSAR/QPER sense) similar to the A_{3} selective antagonists and the ``traditional'' piracetam-like nootropics. they get into K_{ow} being a factor in retention of several of the analogues with similar K_{i}'s, so again, we are looking at substituents on the ring(s) and elsewhere. okay, enough for now. the ring cleavage you mention is certainly probable given the chemistry of all these compounds. however, i have not done my homework on what literature is out there in terms of assaying the by-products of degradation. more later, and all the best, chemist


Share
Tweet  

Thread

 

Post a new follow-up

Your message only Include above post


Notify the administrators

They will then review this post with the posting guidelines in mind.

To contact them about something other than this post, please use this form instead.

 

Start a new thread

 
Google
dr-bob.org www
Search options and examples
[amazon] for
in

This thread | Show all | Post follow-up | Start new thread | FAQ
Psycho-Babble Alternative | Framed

poster:chemist thread:358292
URL: http://www.dr-bob.org/babble/alter/20040613/msgs/363705.html